Moderna Covid vaccine spurs ‘strong immune response, no serious side-effect’ in older adults

  • 6 months   ago
Moderna COVID-1 Vaccine
A phase 1 investigational trial has revealed that the Covid-19 vaccine developed by US-based pharmaceutical company Moderna elicited a strong immune response in older adults with no serious adverse effects, a study has claimed.
 
The vaccine, called mRNA-1273, is being developed by Moderna in partnership with the US government’s National Institutes of Health (NIH). For the trial, 40 adults over the age of 56 were inoculated with the vaccine.
 
 
The researchers involved in the study were drawn from a host of US institutes, including Emory University School of Medicine and the University of Maryland School of Medicine.
 
Moderna helped develop the protocol for the study and provided the vaccine, but had no role in funding. The NIH’s National Institute of Allergy and Infectious Diseases served as sponsor and decision-maker for study design and implementation.
 
According to the results of the study, published in the New England Journal of Medicine (NEJM) on 29 September, the vaccine produced high levels of both binding and neutralising antibodies in older adults.
 
Neutralising antibodies prevent infectious particles from interacting with host cells while binding antibodies can bind to the coronavirus but do not necessarily attack it.
 
The study noted that testing the vaccine on older participants was of “paramount importance” since “these persons account for the majority of serious Covid-19 cases and associated deaths”.
 
It added that the results are also significant because the “immune response to many other vaccines has been shown to decrease with increasing age”.

Source: Source

Comments